Last reviewed · How we verify

Unloxcyt (COSIBELIMAB)

Checkpoint Therapeutics Inc · FDA-approved approved Monoclonal antibody Quality 55/100

Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells.

At a glance

Generic nameCOSIBELIMAB
SponsorCheckpoint Therapeutics Inc
Drug classProgrammed Death Ligand-1 Blocker [EPC]
TargetPd-1
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2024

Mechanism of action

. Mechanism of Action PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Cosibelimab-ipdl binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the anti-tumor immune response. Cosibelimab-ipdl has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: